Core Insights - The core vision of the company is to transform brain-computer interfaces (BCIs) into a universal human-machine interaction technology to address challenges posed by future artificial intelligence [2] - The company has developed a range of products and solutions in just three years, including three core hardware products and eight application software solutions, successfully entering the Ministry of Industry and Information Technology's 2024 future industry project [2] Company Developments - The company has signed a collaboration with a leading domestic new energy vehicle company to integrate its brain-control module into vehicle systems, advancing the relationship between humans and cars from "human-controlled" to "car-understanding" [1] - The company has launched a non-invasive brain-computer interface rehabilitation system that is lightweight and capable of precise signal capture, becoming a valuable tool in clinical rehabilitation [2][3] Applications and Innovations - In the medical rehabilitation field, the company's core products cover a full range of solutions from non-invasive to minimally invasive, addressing various neurological disorders such as stroke and spinal cord injuries [2] - The system captures neural signals from the brain's motor cortex in real-time and translates them into control commands for external devices, creating a closed-loop training system that helps patients rebuild damaged neural pathways [3] - In the education sector, the company is piloting "brain science integrated smart classrooms" in four primary schools in Suzhou, using brainwave devices to assess and train students' concentration [3] Industry Environment - The company has chosen Suzhou for its favorable talent policies and industrial collaboration environment, which supports the hardware production and clinical validation of brain-computer interfaces [3] - The strong manufacturing base and biomedicine industry cluster in Suzhou provide unique support for the company's innovations and partnerships with local integrated circuit companies and rehabilitation hospitals [3] Future Outlook - The company hopes for increased policy support from Suzhou to encourage mid- and downstream ecosystem enterprises to adopt innovative technologies [4] - There is an expectation for brain-computer interface technology to transition from laboratory research to practical products that can be widely adopted [5]

Summary of Xiangya Medical's Conference Call Company Overview - **Company**: Xiangya Medical - **Industry**: Brain-Computer Interface (BCI) and Rehabilitation Equipment Key Points and Arguments Product Development and Market Entry - Xiangya Medical has launched a series of brain-computer interface products, including EEG machines and new products with multimodal technology, covering disease diagnosis and patient rehabilitation. Over 10 non-invasive brain-controlled products are expected to receive registration by Q1 2026, with plans to launch 70-80 new products by the end of the year, totaling over 100 products in the market [2][3][4] - The brain-controlled products have entered over 500 top hospitals, with a target of over 1,000 hospitals by the Lunar New Year of 2027, primarily through clinical research, scientific projects, or procurement methods [2][4] - New devices are classified as Class II medical devices, which do not require clinical trials, representing an upgrade to traditional rehabilitation equipment. The active rehabilitation effect is over 20% better than traditional passive rehabilitation methods, with this percentage continuously improving [2][6] Revenue and Growth Projections - Xiangya Medical anticipates approximately 100 million yuan in revenue from the brain-computer interface business by the end of 2026, despite a macroeconomic downturn, projecting single-digit growth in 2026 and a return to double-digit growth in 2027 [3][19] - The company has established a goal of achieving over 100 million yuan in revenue based on the progress of registration certificates and hospital procurement processes [19] Competitive Advantages - Xiangya Medical has a significant competitive edge in the BCI field due to 10 years of technical accumulation, including hardware, algorithms, and data collection precision. All key components are self-developed, which reduces costs and enhances compatibility with rehabilitation devices [11][12] - The company is the only one in the rehabilitation industry that simultaneously produces self-developed data collection devices and rehabilitation equipment, making it difficult for competitors to catch up quickly [11] Market Demand and Policy Support - There is strong demand and procurement willingness for BCI devices in top hospitals, driven by government policies supporting the industry. Nearly 20 provinces have published related charging directories, accelerating the clinical application of BCI devices [9][10] - The pricing for BCI rehabilitation training is affordable, ranging from tens to over a hundred yuan, which aligns with clinical needs and enhances the market's acceptance [10][16] Non-Medical BCI Products and Future Plans - Xiangya Medical is also developing non-medical BCI products focusing on attention, meditation, and insomnia, with plans to launch consumer-grade products in 2026 [22] - The company has established a robotics research center to focus on rehabilitation robots, with plans for lightweight portable exoskeleton products expected to receive registration in the first half of 2026 [23][25] Clinical Integration and Regulatory Environment - The integration of clinical specialties is increasingly recognized despite current procurement pressures. The company promotes a comprehensive clinical rehabilitation model, which is expected to improve hospital revenue structures in the long term [31] - The DRG system positively impacts the rehabilitation business, with evidence showing that rehabilitation revenue in high-level hospitals can account for one-third of total income [32][33] Conclusion - Xiangya Medical is positioned for significant growth in the BCI and rehabilitation equipment market, leveraging its technological advancements, strong market demand, and supportive government policies to achieve its revenue goals and expand its product offerings in both medical and non-medical applications [3][19][22]